Jennerex's Nexavar rival Pexa-Vec shows promising Phase II efficacy in HCC
This article was originally published in Scrip
Executive Summary
Jennerex published data from a 30-patient Phase II dose comparison study for Pexa-Vec (JX-594) - an oncolytic virus engineered as an immunotherapy - which show the highest dose administered to patients with advanced hepatocellular carcinoma (HCC) may outperform the Bayer and Onyx Pharmaceuticals liver cancer drug Nexavar (sorafenib).